Abstract:The modern healthcare system faces an unrelenting threat from microorganisms, as evidenced by global outbreaks of new viral diseases, emerging antimicrobial resistance, and the rising incidence of healthcare-associated infections (HAIs). An effective response to these threats requires rapid and accurate diagnostic tests that can identify causative pathogens at the point of care (POC). Such tests could eliminate diagnostic uncertainties, facilitating patient triaging, minimizing the empiric use of antimicrobial drugs, and enabling targeted treatments. Current standard methods, however, often fail to meet the needs of rapid diagnosis in POC settings. Culture-based assays entail long processing times and require specialized laboratory infrastructure; nucleic acid (NA) tests are often limited to centralized hospitals due to assay complexity and high costs. Here we discuss two new POC tests developed in our groups to enable the rapid diagnosis of infection. The first is nanoPCR that takes advantages of core-shell magnetoplasmonic nanoparticles (MPNs): (i) Au shell significantly accelerates thermocycling via volumetric, plasmonic light-to-heat conversion and (ii) a magnetic core enables sensitive in situ fluorescent detection via magnetic clearing. By adopting a Ferris wheel module, the system expedites multisamples in parallel with a minimal setup. When applied to COVID-19 diagnosis, nanoPCR detected SARS-CoV-2 RNA down to 3.2 copy/μL within 17 min. In particular, nanoPCR diagnostics accurately identified COVID-19 cases in clinical samples (n = 150), validating its clinical applicability. The second is a polarization anisotropy diagnostic (PAD) system that exploits the principle of fluorescence polarization (FP) as a detection modality. Fluorescent probes were designed to alter their molecular weight upon recognizing target NAs. This event modulates the probes' tumbling rate (Brownian motion), which leads to changes in FP. The approach is robust against environmental noise and benefits from the ratiometric nature of the signal readout. We applied PAD to detect clinically relevant HAI bacteria (Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus). The PAD assay demonstrated detection sensitivity down to the single bacterium level and determined both drug resistance and virulence status. In summary, these new tests have the potential to become powerful tools for rapid diagnosis in the infectious disease space. They do not require highly skilled personnel or labor-intensive analyses, and the assays are quick and cost-effective. These attributes will make nanoPCR and PAD well-aligned with a POC workflow to aid physicians to initiate prompt and informed patient treatment.

Needle‐Plug/Piston‐Based Modular Mesoscopic Design Paradigm Coupled With Microfluidic Device for Point‐of‐Care Pooled Testing

Needle-Plug/Piston-Based Modular Mesoscopic Design Paradigm Coupled with Microfluidic Device for Point-of-Care Pooled Testing

Fully Integrated and High-Throughput Microfluidic System for Multiplexed Point-Of-Care Testing.

A Fully Integrated<em> in Vitro</em> Diagnostic Microsystem for Pathogen Detection Developed Using a &ldquo;3d Extensible&rdquo; Microfluidic Design Paradigm

Portable all-in-one microfluidic system for CRISPR-Cas13a-based fully integrated multiplexed nucleic acid detection

Pipette-operable microfluidic devices with hydrophobic valves in sequential dispensing with various liquid samples: multiplex disease assay by RT-LAMP

A Portable System for Economical Nucleic Acid Amplification Testing

A Fully Integrated In Vitro Diagnostic Microsystem for Pathogen Detection Developed Using a "3D Extensible" Microfluidic Design Paradigm.

Fully integrated and automated centrifugal microfluidic chip for point-of-care multiplexed molecular diagnostics

Hermetic Microfluidic Device for Point-of-care Viral Nucleic Acid Testing

Self-Priming Compartmentalization Digital Lamp For Point-Of-Care

All-in-one microfluidic chip for 30-min quantitative point-of-care-testing of nucleic acids

Integrated Microwell Array-Based Microfluidic Chip with a Hand-Held Smartphone-Controlled Device for Nucleic Acid Detection

A pocket-sized device automates multiplexed point-of-care RNA testing for rapid screening of infectious pathogens

A Fully Integrated in vitro Diagnostic Microsystem

Handheld Microfluidic Filtration Platform Enables Rapid, Low‐Cost, and Robust Self‐Testing of SARS‐CoV‐2 Virus

Development of Integrated Systems for On-Site Infection Detection

Integrated Microfluidic Systems with Sample Preparation and Nucleic Acid Amplification.

An integrated microfluidic platform for nucleic acid testing

Integrated High-Throughput Centrifugal Microfluidic Chip Device for Pathogen Detection On-Site

Multiple on-line active valves based centrifugal microfluidics for dynamic solid-phase enrichment and purification of viral nucleic acid